ClinicalTrials.gg
Active, not recruitingNCT04622319Updated May 15, 2026

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

A Phase 3 interventional study of DS-8201a and T-DM1 in HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer, sponsored by Daiichi Sankyo. Active, not recruiting at 482 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Planned enrollment
Largest of 58
1,600 · median 139
Started
2020
with 8 others
Phase 3
12 of 58
3 open now
Primary completion
2025-07
later than 6 of 44 live
Registered
17th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one has the largest planned enrollment, is one of 9 that started in 2020, is one of 12 in phase 3, reaches primary completion later than 6 of the 44 other live ones, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Read the detailed description

This study will examine trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary BC who have residual invasive disease in breast or axillary lymph nodes with higher risk of recurrence, which includes patients who were inoperable at disease presentation or had pathological node-positive status after neoadjuvant therapy.

The primary objective is to compare invasive disease-free survival (IDFS) between T-DXd and T-DM1 treatment arms in this population. The key secondary objective of the study is to evaluate disease-free survival (DFS).

03

Conditions studied

  • HER2-Positive Primary Breast Cancer
  • Residual Invasive Breast Cancer

Browse trials for

Keywords

  • HER2-Positive Primary Breast Cancer
  • Residual Invasive Breast Cancer
  • Trastuzumab Deruxtecan
  • Trastuzumab Emtansine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults ≥18 years old (local regulatory requirements will apply if the legal age of consent for study participation is >18 years old).
  • documented -positive breast cancer (BC):

    • HER2-positive expression defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) confirmed prior to study randomization.
  • Histologically confirmed invasive breast carcinoma.
  • Clinical stage at disease presentation: T1-4, N0-3, M0; patients presenting with T1N0 tumors are not eligible.
  • Pathologic evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of therapy meeting one of the following high-risk criteria:

    • Inoperable breast cancer at presentation (prior to neoadjuvant therapy), defined as clinical stages T4, N0-3, M0 or T1-3, N2-3, M0.
    • Operable at presentation, defined as clinical stages T1-3,N0-1,M0, with axillary node positive disease (ypN1-3) following neoadjuvant therapy.
  • Completion of neoadjuvant systemic therapy, including taxane-based chemotherapy and HER2-directed treatment prior to surgery.

    • Systemic therapy must consist of at least 6 cycles of neoadjuvant therapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab (± pertuzumab) and at least 9 weeks of taxane-based chemotherapy to be completed prior to surgery. Patients may have received an anthracycline as part of neoadjuvant therapy in addition to taxane chemotherapy.
  • Adequate excision as confirmed per medical records: surgical removal of all clinically evident disease in the breast and axillary lymph nodes.
  • An interval of no more than 12 weeks between the date of last surgery and the date of randomization.
  • Known hormone receptor (HR) status, per local laboratory assessment, as defined by ASCO-CAP guidelines (≥1%): HR positive status defined by either positive estrogen receptor (ER) and/or positive progesterone receptor (PR).

status. HR-negative status defined by both known negative ER and known negative PR.

  • (LVEF) ≥50% within 28 days prior to randomization.
  • (ECOG) performance status of 0 or 1 at Screening.
  • Has adequate organ function within 14 days before randomization.

Key Exclusion Criteria:

  • Stage IV () BC.
  • History of any prior (ipsi- or contralateral) breast cancer except lobular carcinoma in situ (LCIS).
  • Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery.
  • Prior treatment with T-DXd, T-DM1 or other anti-HER2 antibody-drug conjugate (ADC) or prior enrollment in a clinical study of T-DXd (regardless of treatment arm)
  • History of exposure to the following cumulative doses of anthracyclines:

    • Doxorubicin > 240 mg/m\^2
    • Epirubicin or Liposomal Doxorubicin-Hydrochloride > 480 mg/m\^2
    • For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m\^2
  • History of other within the last 5 years except for appropriately treated CIS of the cervix, nonmelanoma skin carcinoma, Stage I melanoma skin carcinoma, Stage I uterine cancer, or other appropriately treated non-breast malignancies with an outcome similar to those mentioned above.
  • History of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required and/or has ILD/pneumonitis noted on computed tomography (CT) scan of the chest at Screening (asymptomatic interstitial changes confined to recent radiation therapy fields are not excluded).
  • Known pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within three months prior to randomization, severe asthma, severe [COPD], restrictive lung disease).
  • Any , connective tissue or inflammatory disorders (eg, Rheumatoid arthritis, Sjogren's, sarcoidosis, etc) where there is documented or a suspicion of pulmonary involvement or pneumonectomy at the time of screening.
  • Medical history of myocardial infarction (MI) within 6 months before randomization, symptomatic congestive heart failure (CHF) ( Class II to IV), troponin levels consistent with MI as defined according to the manufacturer 28 days prior to randomization.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,600 participants (estimated)

Study arms

  • Experimental
    Trastuzumab deruxtecan (T-DXd)

    Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.

    Drug: DS-8201a

  • Active comparator
    Trastuzumab ematansine (T-DM1)

    Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.

    Drug: T-DM1

Interventions

  • Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle

    Also known as: Trastuzumab deruxtecan (T-DXd)

  • DrugT-DM1

    Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle

    Also known as: Trastuzumab emtansine (T-DM1)

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Randomization to date of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first), up to approximately 57 months postdose

Secondary outcomes

  1. Disease-free Survival (DFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Randomization to date of the first occurrence of an IDFS event including second primary non-breast cancer event or contralateral or ipsilateral ductal carcinoma in situ (whichever occurs first), up to approximately 81 months postdose

  2. Overall Survival (OS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Randomization to date of death from any cause, up to approximately 81 months postdose

  3. Distant Recurrence-free Interval (DRFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Randomization to date of distant recurrence, up to approximately 81 months postdose

  4. Brain Metastases-free Interval (BMFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Randomization to date of brain metastasis, up to approximately 81 months postdose

  5. Percentage of Treatment-emergent Adverse Events in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

    Time frame: Baseline up to approximately 81 months postdose

  6. Serum Concentrations of Trastuzumab Deruxtecan (T-DXd), total anti-HER2 antibody, and Active Metabolite MAAA-1181a

    Time frame: Pre-dose on Day 1 of Cycles 1, 4 and 10 and within 15 minutes post-dose on Day 1 of Cycles 1 and 4 (each cycle is 21 days)

  7. Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd)

    Time frame: Baseline up to approximately 81 months postdose

07

Study locations

482 sites
  • The Oncology Institute of Hope & Innovation
    Anaheim, California 92801, United States
  • Kaiser Permanente
    Anaheim, California 92806, United States
  • Kaiser Permanente
    Baldwin Park, California 91706, United States
  • Kaiser Permanente
    Bellflower, California 90706, United States
  • Kaiser Permanente
    Fontana, California 92335, United States
  • Orange Coast Blood and Cancer Care
    Fountain Valley, California 92708, United States
  • Kaiser Permanente
    Harbor City, California 90710, United States
  • Kaiser Permanente
    Irvine, California 92618, United States
  • Long Beach Memorial TCI
    Long Beach, California 90806, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Kaiser Permanente
    Ontario, California 90710, United States
  • Kaiser Permanente
    Panorama City, California 91402, United States
  • Kaiser Permanente
    Riverside, California 92505, United States
  • Kaiser Permanente
    San Diego, California 92120, United States
  • Kaiser Permanente
    San Marcos, California 92078, United States
  • Kaiser Permanente
    West Los Angeles, California 90034, United States
  • Kaiser Permanente
    Woodland Hills, California 91367, United States
  • SCRI FCS North- Altamonte
    Altamonte Springs, Florida 32701, United States
  • SCRI FCS South- Bonita
    Bonita Springs, Florida 34135, United States
  • SCRI FCS North- Brandon Cancer Center
    Brandon, Florida 33511, United States
  • SCRI FCS South- North Fort Myers
    Cape Coral, Florida 33909, United States
  • SCRI FCS North- Mease/Clearwater
    Clearwater, Florida 33761, United States
  • SCRI FCS South
    Fort Myers, Florida 33901, United States
  • SCRI FCS South- Colonial
    Fort Myers, Florida 33905, United States
  • SCRI FCS South- Gladiolus
    Fort Myers, Florida 33908, United States
  • SCRI FCS North- Gainesville Cancer Center
    Gainesville, Florida 32605, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • SCRI FCS North- Villages East
    Lady Lake, Florida 32159, United States
  • SCRI FCS South- Lakewood Ranch
    Lakewood Rch, Florida 34211, United States
  • SCRI FCS North- Largo/Highland
    Largo, Florida 33770, United States
  • SCRI FCS North- Lecanto
    Lecanto, Florida 34461, United States
  • SCRI FCS South- Naples West
    Naples, Florida 34102, United States
  • SCRI FCS South- Naples/Goodlette
    Naples, Florida 34119, United States
  • SCRI FCS North- New Port Richey
    New Port Richey, Florida 34655, United States
  • SCRI FCS North- Ocala
    Ocala, Florida 34474, United States
  • Orlando Health
    Ocoee, Florida 34761, United States
  • SCRI FCS North- Orange City
    Orange City, Florida 32763, United States
  • Orlando Health
    Orlando, Florida 32806, United States
  • SCRI FCS North- Orlando Downtown
    Orlando, Florida 32806, United States
  • SCRI FCS South- Port Charlotte
    Port Charlotte, Florida 33980, United States
  • SCRI FCS South- Sarasota-Cattleman
    Sarasota, Florida 34232, United States
  • SCRI FCS South-Sarasota-Downtown
    Sarasota, Florida 34236, United States
  • SCRI FCS North- Spring Hill
    Spring Hill, Florida 34608, United States
  • SCRI FCS North- St. Anthony's/St. Petersburg
    St. Petersburg, Florida 33705, United States
  • SCRI FCS North
    St. Petersburg, Florida 33705, United States
  • SCRI FCS North- Tampa Cancer Center
    Tampa, Florida 33607, United States
  • SCRI FCS North- Tavares
    Tavares, Florida 32778, United States
  • SCRI FCS South- Venice Healthpark
    Venice, Florida 34292, United States
  • Cleveland Clinic-Weston
    Weston, Florida 33326, United States
  • SCRI FCS North- Winter Park
    Winter Park, Florida 32792, United States
  • Elmhurst Memorial Hospital- Nancy W. Knowles Cancer Center
    Elmhurst, Illinois 60126, United States
  • Edward Cancer Center
    Naperville, Illinois 60540, United States
  • Edward Cancer Center Plainfield
    Plainfield, Illinois 60585, United States
  • University of Kentucky, Markey Cancer Center, Clinical Research Organization
    Lexington, Kentucky 40536, United States
  • Baptist Health Louisville
    Louisville, Kentucky 40207, United States
  • LSU Health Baton Rouge North Clinic
    Baton Rouge, Louisiana 70805, United States
  • Our Lady of the Lake Physician Group-Medical Oncology
    Baton Rouge, Louisiana 70808, United States
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
  • Ochsner Hematology Oncology North Shore - Covington (West Region)
    Covington, Louisiana 70433, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • MedStar Franklin Square Medical Center-Harry and Jeanette Weinberg Cancer Institute
    Baltimore, Maryland 21237, United States
  • MedStar Franklin Square Cancer Center at Loch Raven Campus
    Baltimore, Maryland 21239, United States
  • Frederick Health-James M Stockman Cancer Center
    Frederick, Maryland 21702, United States
  • Maryland Oncology Hematology
    Silver Spring, Maryland 20904, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Waverly Hematology Oncology
    Cary, North Carolina 27518, United States
  • UNC Cancer Care at Nash
    Rocky Mount, North Carolina 27804, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic - Hillcrest
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic-Fairview
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic South Pointe
    Warrensville Heights, Ohio 44195, United States
  • UPMC Upper St. Clair
    Bethel Park, Pennsylvania 15102, United States
  • UPMC Passavant Cranberry/North
    Cranberry Township, Pennsylvania 16066, United States
  • UPMC Erie
    Erie, Pennsylvania 16505, United States
  • AHN Cancer Inst at St Vincent
    Erie, Pennsylvania 16544, United States
  • UPMC Arnold Palmer-Mt View
    Greensburg, Pennsylvania 15601, United States
  • UPMC Pinnacle-Ortenzio Cancer Center
    Harrisburg, Pennsylvania 17050, United States
  • UMPC Pinnacle Pharmacy
    Harrisburg, Pennsylvania 17109, United States
  • AHN Cancer Insititute at Jefferson
    Jefferson Hills, Pennsylvania 15025, United States
  • AHN Cancer Institute at Forbes
    Monroeville, Pennsylvania 15146, United States
  • UPMC Monroeville
    Monroeville, Pennsylvania 15146, United States
  • UPMC Arnold Palmer-Mt Pleasant
    Mount Pleasant, Pennsylvania 15666, United States
  • UPMC Arnold Palmer-Norwin
    N. Huntingdon, Pennsylvania 15642, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Magee
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC St. Margaret
    Pittsburgh, Pennsylvania 15215, United States
  • AHN Cancer Inst at West Penn
    Pittsburgh, Pennsylvania 15224, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • UPMC Passavant HOA
    Pittsburgh, Pennsylvania 15237, United States
  • UPMC Passavant OHA
    Pittsburgh, Pennsylvania 15237, United States
  • UPMC Uniontown
    Uniontown, Pennsylvania 15401, United States
  • UPMC Washington
    Washington, Pennsylvania 15301, United States
  • Reading Hospital, McGlinn Cancer Institute
    West Reading, Pennsylvania 19611, United States
  • AHN Cancer Institute at Wexford
    Wexford, Pennsylvania 15090, United States
  • UPMC Pinnacle-Memorial Cancer Center
    York, Pennsylvania 17408, United States
  • SCRI TO Nashville- Franklin Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • SCRI TO Nashville- Gallatin Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • SCRI TO Nashville- Hendersonville Tennessee Oncology, PLLC
    Hendersonville, Tennessee 37075, United States

Showing the first 100 of 482 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramirez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr; DESTINY-Breast05 Trial Investigators. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661. Epub 2025 Dec 10. PubMed 41370739 ↗
  • Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093. PubMed 40073831 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2025, 54 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 54 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Nov 9, 2020
StartActual
Dec 4, 2020
Primary completionActual
Jul 2, 2025
CompletionEst.
Jun 20, 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04622319
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group (SOLTI)
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Dec 4, 2020
Primary completion
Jul 2, 2025
Completion
Jun 20, 2028 (estimated)
Last update
May 15, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion